Inogen (NASDAQ: INGN) reported Q2 EPS of $0.17, versus $0.11 reported last year. Revenue for the quarter came in at $44 million, versus $30.4 thousand reported last year.

Inogen raised FY2015 revenue guidance to $145-149 million, versus prior guidance of $133-137 million.

"Our record revenues in the second quarter reflect exceptionally strong performance across all of our sales channels, as well as the benefit of seasonality. Net income and Adjusted EBITDA also reached record levels, demonstrating our substantial operating cost leverage," said President and Chief Executive Officer, Raymond Huggenberger. "As we look out towards the second half of this year, we expect to see stronger than originally anticipated demand continue, and as a result, are updating our guidance for 2015 accordingly."

Financial Outlook for 2015

Inogen is increasing its 2015 revenue guidance to a range of $145 to $149 million, which represents year-over-year growth of 28.8% to 32.4%. This compares to the previous revenue expectation of $133 to $137 million. This increase in guidance is associated with better than expected business-to-business revenue worldwide. The Company typically sees the highest revenue seasonality in the second quarter of the year when patients are more likely to travel and as a result purchase or rent its products.

The Company is also increasing its 2015 Adjusted EBITDA estimate to a range of $29 to $32 million, representing an increase of 21.1% to 33.6% over 2014. This is updated from prior guidance of $27 to $30 million.

Net income for 2015 is currently expected to be in the range of $8.5 to $10 million, representing an approximate increase of 24.5% to 46.5% over 2014. This is updated from a prior range of $8 to $9.5 million. The one-time general and administrative operating expenses of $1.8 million associated with the audit committee investigation are included in this guidance, and all expenses were incurred during the six-month period ended June 30, 2015.

The Company continues to expect an effective tax rate in 2015 of approximately 35%.

The Company also confirms its expectation of net positive cash flow for 2015 with no additional equity capital required to meet its current plan.

For earnings history and earnings-related data on Inogen (INGN) click here.